Visceral fat area and cardiometabolic risk: The Kardiovize study.

Autor: Polcrova A; International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic; Research Centre for Toxic Compounds in the Environment (RECETOX), Masaryk University, Brno, Czech Republic. Electronic address: anna.polcrova@fnusa.cz., Pavlovska I; International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic; Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Maranhao Neto GA; International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic., Kunzova S; International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic., Infante-Garcia MM; Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela., Medina-Inojosa JR; Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, USA., Lopez-Jimenez F; Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, USA., Mechanick JI; The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Heart, and Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Nieto-Martinez R; Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela; Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA; LifeDoc Health, Memphis, TN, USA., Stokin GB; International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic., Pikhart H; Research Centre for Toxic Compounds in the Environment (RECETOX), Masaryk University, Brno, Czech Republic; Department of Epidemiology and Public Health, University College London, United Kingdom., Gonzalez-Rivas JP; International Clinical Research Center (ICRC), St Anne's University Hospital Brno (FNUSA), Czech Republic; Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas, Venezuela; Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Obesity research & clinical practice [Obes Res Clin Pract] 2021 Jul-Aug; Vol. 15 (4), pp. 368-374. Date of Electronic Publication: 2021 Mar 18.
DOI: 10.1016/j.orcp.2021.03.005
Abstrakt: Background: Visceral fat is associated with adiposity-based complications. Bioimpedance measurement allows estimation of visceral fat area (VFA) in an easy manner. However, a validated cut-off value for VFA by bioimpedance associated with cardiometabolic risk is lacking in European population.
Aim: To determine cut-off values of VFA measured via bioimpedance associated with cardiometabolic risk.
Methods: Random cross-sectional Czech population-based sample of 25-64 years old subjects. Receiver Operating Characteristic (ROC) curves were used and the area under the curve (AUC), sensitivity, and specificity were calculated. The Cardiometabolic Disease Staging System (CMDS) was used to classify cardiometabolic risk: Stage 1 - 1 or 2 metabolic syndrome (MetS) components, without impaired fasting glucose (IFG); Stage 2 - MetS or IFG; Stage 3 - MetS with IFG; Stage 4 - type 2 diabetes and/or cardiovascular disease.
Results: 2052 participants (54.5% females, median age 49 years) were included. Median VFA (inter-quartile range) were 82.2 cm 2 (54.8) in men and 89.8 cm 2 (55.6) in women. The best VFA cut-offs associated with Stage 1 in men and women were 71 cm 2 (sensitivity = 0.654; specificity = 0.427) and 83 cm 2 (sensitivity = 0.705; specificity = 0.556) ; Stage 2: 84 cm 2 (sensitivity = 0.673; specificity = 0.551) and 98 cm 2 (sensitivity = 0.702; specificity = 0.628) ; Stage 3: 90 cm 2 (sensitivity = 0.886; specificity = 0.605) and 109 cm 2 (sensitivity = 0.755; specificity = 0.704); Stage 4: 91 cm 2 (sensitivity = 0.625; specificity = 0.611) and 81 cm 2 (sensitivity = 0.695; specificity = 0.448), respectively.
Conclusion: A cut-off value of VFA of 71 cm 2 in men and 83 cm 2 in women exhibited the earliest stage of cardiometabolic risk, and 90 cm 2 in men and 109 cm 2 in women showed the best performance to detect risk.
(Copyright © 2021 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: